CA4236943060
© Newsfile
11.12.2025
HEM
LISTED
TSX
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
News Preview
Thomas Smeenk, BA, unveils a proposed conformal invariant, A = E/(hv), explored as a potential bridge between General Relativity, Quantum Mechanics, cosmology, and string theory.Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) the leading autologous (patient's own) stem cell therapy com...
Themefolio
Profiler
Peergroup
© Newsfile
11.12.2025
HEM
LISTED
TSX
Hemostemix Grants Stock Options
News Preview
Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on December 11, 2025, subject to regulatory approval, a total of 963,000 stock options to purchase common shares of Hemo...
Themefolio
Profiler
Peergroup
© Newsfile
10.12.2025
HEM
LISTED
TSX
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
News Preview
Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from vascular dementia, angina, ischemic cardiomyopathy, congestive heart failure,...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Newsfile
04.12.2025
HEM
LISTED
TSX
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
News Preview
Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for ischemic diseases, is pleased to announce the appointment of Shaune Harding, OStJ, RN non-practicing, as Director of Patient Care & Clinical Operations....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
03.12.2025
HEM
LISTED
TSX
Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14
News Preview
Calgary, Alberta--(Newsfile Corp. - December 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its participation as a premier regenerative medicine company at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, where global leaders in vascular surgery, wound...
Themefolio
Profiler
Peergroup
© Newsfile
02.12.2025
HEM
LISTED
TSX
Hemostemix to Attend DFCon San Antonio and Closed its Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - December 2, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preservation Society in San Antonio, Texas - the global epicentre for innovation in diabetic foot care, vascular medicine, and limb preservation. With more than 5...
Themefolio
Profiler
Peergroup
© Newsfile
26.11.2025
HEM
LISTED
TSX
Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two
News Preview
Calgary, Alberta--(Newsfile Corp. - November 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), is pleased to announce a binding Letter of Intent for the acquisition of the first two cardiology practices under the Company's clinic roll-up and commercialization strategy. The practices of Dr. Roberto Manuel Fernandez-de-Castro and Dr...
Themefolio
Profiler
Peergroup
© Newsfile
20.11.2025
HEM
LISTED
TSX
Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia
News Preview
Calgary, Alberta--(Newsfile Corp. - November 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option patients suffering from pain, angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy,...
Themefolio
Profiler
Peergroup
© Newsfile
18.11.2025
HEM
LISTED
TSX
Hemostemix Closes CDN$280,594 Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ische...
Themefolio
Profiler
Peergroup
© Newsfile
18.11.2025
HEM
LISTED
TSX
Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida
News Preview
Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a leader in regenerative medicine, will attend the Innovations in Wound Care Conference from December 11-14, 2025 in Key West, Florida. The company will highlight its world-leading angiogenic cell therapy, ACP-01, which regenerates circu...
Themefolio
Profiler
Peergroup
© Newsfile
13.11.2025
HEM
LISTED
TSX
Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway
News Preview
Session led by neurosurgeon Dr. Fraser Henderson and Hemostemix CEO Thomas Smeenk for the University of Florida's Department of Surgery, Division of Vascular Surgery & Endovascular Therapy (Gainesville)Calgary, Alberta--(Newsfile Corp. - November 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced key highlights from...
Themefolio
Profiler
Peergroup
© Newsfile
04.11.2025
HEM
LISTED
TSX
Hemostemix Closes Private Placement of $461,230
News Preview
Calgary, Alberta--(Newsfile Corp. - November 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chron...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
30.10.2025
HEM
LISTED
TSX
Hemostemix's Boots on the Ground in Florida October Update
News Preview
Calgary, Alberta--(Newsfile Corp. - October 30, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic car...
Themefolio
Profiler
Peergroup
© Newsfile
28.10.2025
HEM
LISTED
TSX
Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTI
News Preview
Calgary, Alberta--(Newsfile Corp. - October 28, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic car...
Themefolio
Profiler
Peergroup
© Newsfile
22.10.2025
HEM
LISTED
TSX
Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42
News Preview
Calgary, Alberta--(Newsfile Corp. - October 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non...
Themefolio
Profiler
Peergroup
© Newsfile
15.10.2025
HEM
LISTED
TSX
Hemostemix Adds the Treatment of Refractory Angina to Its Phase 1 Basket Protocol
News Preview
Calgary, Alberta--(Newsfile Corp. - October 15, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non...
Themefolio
Profiler
Peergroup
© Newsfile
09.10.2025
HEM
LISTED
TSX
Hemostemix Files for Ethics Approval of its Study of Vascular Dementia
News Preview
Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has filed its Institutional Review Board (IRB) application for approval of its Phase 1 clinical trial titled "Treatment of Vascular Cognitive Impairment and Dementia with Angiogenic Cell...
Themefolio
Profiler
Peergroup
© Newsfile
07.10.2025
HEM
LISTED
TSX
Hemostemix's Insider Lead Order of $330,000 Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - October 7, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce a lead order of $330,000 for a non brokered private placement of up to $700,000.Purchasers may subscribe for Units at $0.11. Each Unit consists of one Common Share and one Warrant. Each Warr...
Themefolio
Profiler
Peergroup
© Newsfile
23.09.2025
HEM
LISTED
TSX
Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell(TM)) Across Multiple Ischemic and Vascular Indications Simultaneously
News Preview
Calgary, Alberta--(Newsfile Corp. - September 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, n...
Themefolio
Profiler
Peergroup
© Newsfile
17.09.2025
HEM
LISTED
TSX
Hemostemix to Present at Life Science Investor Forum
News Preview
Calgary, Alberta--(Newsfile Corp. - September 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemi...
Themefolio
Profiler
Peergroup
© Newsfile
16.09.2025
HEM
LISTED
TSX
Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina
News Preview
Calgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemi...
Themefolio
Profiler
Peergroup
© Newsfile
10.09.2025
HEM
LISTED
TSX
Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share
News Preview
Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy,...
Themefolio
Profiler
Peergroup
© Newsfile
09.09.2025
HEM
LISTED
TSX
Hemostemix Announces Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic...
Themefolio
Profiler
Peergroup
© Newsfile
09.09.2025
HEM
LISTED
TSX
Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients
News Preview
Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic...
Themefolio
Profiler
Peergroup
© Newsfile
04.09.2025
HEM
LISTED
TSX
Hemostemix's VesCell.Health Launched in Florida
News Preview
Calgary, Alberta--(Newsfile Corp. - September 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic...
Themefolio
Profiler
Peergroup
© Newsfile
03.09.2025
HEM
LISTED
TSX
Howie's 17+ Years After VesCell(TM): Following Hemostemix's Heart Patients
News Preview
Calgary, Alberta--(Newsfile Corp. - September 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic...
Themefolio
Profiler
Peergroup
© Newsfile
28.08.2025
HEM
LISTED
TSX
Hemostemix Announces Financing Plans for VesCell(TM) Treatment
News Preview
Calgary, Alberta--(Newsfile Corp. - August 28, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated c...
Themefolio
Profiler
Peergroup
© Newsfile
26.08.2025
HEM
LISTED
TSX
Hemostemix's Boots on the Ground in Florida
News Preview
Calgary, Alberta--(Newsfile Corp. - August 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated c...
Themefolio
Profiler
Peergroup
© Newsfile
20.08.2025
HEM
LISTED
TSX
Hemostemix's Social Media for Investors and Florida's No-Option Patients
News Preview
Calgary, Alberta--(Newsfile Corp. - August 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Isch...
Themefolio
Profiler
Peergroup
© Newsfile
19.08.2025
HEM
LISTED
TSX
Hemostemix Announces Its AI Strategy
News Preview
Calgary, Alberta--(Newsfile Corp. - August 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company treating no-option patients in Florida suffering in pain from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease and Angina, is p...
Themefolio
Profiler
Peergroup
© Newsfile
14.08.2025
HEM
LISTED
TSX
Hemostemix's Expands its Marketing Team Focused on Sales in Florida
News Preview
Calgary, Alberta--(Newsfile Corp. - August 14, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous stem cell company developing and commercializing VesCell™ (ACP-01), announces the appointment of a seasoned commercial team encompassing marketing, sales, e-commerce and patient care communications, in compliance with f...
Themefolio
Profiler
Peergroup
© Newsfile
12.08.2025
HEM
LISTED
TSX
Hemostemix Contracts Empire Market Ventures to Increase Market Awareness
News Preview
Calgary, Alberta--(Newsfile Corp. - August 12, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it contracted Empire Market Ventures to provide an investor market awareness program. Empire Market Ventures (EMV) is a premier consulting firm and full-service advertising and investor awareness agency based in New York C...
Themefolio
Profiler
Peergroup
© Newsfile
31.07.2025
HEM
LISTED
TSX
Hemostemix Increases Previously Closed Private Placement to $3,000,000
News Preview
Calgary, Alberta--(Newsfile Corp. - July 31, 2025) - Further to its press release dated July 24, 2025, Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") wishes to provide an update regarding its previously closed non-brokered private placement (the "Offering").The Company confirms that, following the receipt of...
Themefolio
Profiler
Peergroup
© Newsfile
31.07.2025
HEM
LISTED
TSX
Cells: Hemostemix ACP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants
News Preview
Calgary, Alberta--(Newsfile Corp. - July 31, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is excited to highlight a groundbreaking research article published in Cells on June 29, 2025, by Fraser C. Henderson Sr. and Ms. Kelly Tuchman, exploring how a combination of the patient's own ACP...
Themefolio
Profiler
Peergroup
© Newsfile
24.07.2025
HEM
LISTED
TSX
Hemostemix Closes $2,969,600 Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - July 24, 2025) - Further to Hemostemix Inc's (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") June 26 and July 9th press releases, the Company is pleased to announce that it has completed its previously announced non-brokered private placement (the "Offering") for gross proceeds of $2,969,60...
Themefolio
Profiler
Peergroup
© Newsfile
23.07.2025
HEM
LISTED
TSX
Hemostemix Closes Sale of 23rd ACP-01 Therapy Convertible Debenture
News Preview
Calgary, Alberta--(Newsfile Corp. - July 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely treated 498 patients for various forms of cardiovascular disease, including peripheral arterial disease, chronic limb threatening ischemia, non ischem...
Themefolio
Profiler
Peergroup
© Newsfile
17.07.2025
HEM
LISTED
TSX
Hemostemix Closing $3,000,000 Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - July 17, 2025) - Further to the June 26 and July 9th press releases announcing the Hemostemix Inc's (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") non-brokered private placement of $2,500,000 and its oversubscription, the Company has accepted additional over-subscriptions totalling $500,00...
Themefolio
Profiler
Peergroup
© Newsfile
09.07.2025
HEM
LISTED
TSX
Hemostemix Oversubscribed, Closing $2,700,000 Private Placement and Settles $400,000 of Debt at $0.20 per Share
News Preview
Calgary, Alberta--(Newsfile Corp. - July 9, 2025) - Hemostemix Inc's (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") non brokered private placement of $2,500,000 announced June 26 is oversubscribed. The Company will close the first tranche of $ 2,700,000, subject to the TSX Venture Exchange ("TSXV") approval on July 10, 2025....
Themefolio
Profiler
Peergroup
© Newsfile
04.07.2025
HEM
LISTED
TSX
Hemostemix Closes $469,366 Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that the TSX Venture Exchange ("TSXV") conditionally approved the Company's previously disclosed non-brokered private placement (the "Offering") in the amount of CAD $469,366. The Offering consisted of...
Themefolio
Profiler
Peergroup
© Newsfile
03.07.2025
HEM
LISTED
TSX
Hemostemix Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to BioCardia's Cardiamp Heart Failure Trial
News Preview
Calgary, Alberta--(Newsfile Corp. - July 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to share the Journal of Biomedical Research and Environmental Science published Autologous Angiogenic Cell Precursors-A Molecular Strategy for The Treatment of Heart Failure: Response to BioCardia's Cardiamp HF Trial.Recent...
Themefolio
Profiler
Peergroup
© Newsfile
27.06.2025
HEM
LISTED
TSX
Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch
News Preview
Calgary, Alberta--(Newsfile Corp. - June 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III autologous stem cell therapy company and Mr. Croom Lawrence are pleased to announce Croom has joined Hemostemix as its Chief Commercialization Officer, and partnered to offer MCI Screen through Hemostemix. MCI Screen is an FDA-approv...
Themefolio
Profiler
Peergroup
© Newsfile
26.06.2025
HEM
LISTED
TSX
Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture
News Preview
Calgary, Alberta--(Newsfile Corp. - June 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces its Chairman, Peter Lacey, has provided the Company with a lead order for a non brokered private placement in the amount of $1,500,000 for Units at $0.10. Each Unit will consist of one...
Themefolio
Profiler
Peergroup
© Newsfile
17.06.2025
HEM
LISTED
TSX
Hemostemix Closes Private Placement of $469,366
News Preview
Calgary, Alberta--(Newsfile Corp. - June 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces the closing of a non brokered private placement with in the amount of CAD $469,366 by the issuance of 3,911,385 Common Shares at CAD $0.12 each, subject to the approval of the TSXV Exchange. All secu...
Themefolio
Profiler
Peergroup
© Newsfile
20.05.2025
HEM
LISTED
TSX
Hemostemix Presents at TERMIS 2025, Freiburg, Germany
News Preview
Freiburg, Germany--(Newsfile Corp. - May 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III clinical-stage biotechnology company developing autologous stem cell therapies for cardiovascular diseases, is presenting its groundbreaking clinical trial results and regenerative medicine innovations today at the Tissue Engineering...
Themefolio
Profiler
Peergroup
© Newsfile
12.05.2025
HEM
LISTED
TSX
Hemostemix Closes Private Placement of USD $336,500 at $0.295 per Share
News Preview
Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), per the Company's February 4, 2025 news release, closed the previously announced USD $336,500 non-brokered private placement, issuing 1,634,466 Common Shares at CAD $0.295 each to CytoImmune Therapeutics LLC, f...
Themefolio
Profiler
Peergroup
© Newsfile
08.05.2025
HEM
LISTED
TSX
Hemostemix at Invest Stuttgart
News Preview
Calgary, Alberta--(Newsfile Corp. - May 8, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is poised to make a significant impact at Invest Stuttgart 2025, Germany's premier finance and investment conference, taking place from May 9-10, 2025 at Messe Stuttgart. The event attracts thousands of inv...
Themefolio
Profiler
Peergroup
© Newsfile
23.04.2025
HEM
LISTED
TSX
Hemostemix Engages PatentVest to Strengthen its Global Patent Portfolio
News Preview
Calgary, Alberta--(Newsfile Corp. - April 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) a leader in the development of autologous stem cell therapy for the treatment of cardiovascular diseases, announces its partnership with PatentVest. PatentVest, a subsidiary of MDB Capital (NASDAQ: MDBH), is a premier intellectual property s...
Themefolio
Profiler
Peergroup
© Newsfile
17.03.2025
HEM
LISTED
TSX
Hemostemix's Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial
News Preview
Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, pitched the treatment of Vascular Dementia with ACP-01 to Wall Street."The specificity of A...
Themefolio
Profiler
Peergroup
© Newsfile
06.03.2025
HEM
LISTED
TSX
Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01
News Preview
A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementiaCalgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treat...
Themefolio
Profiler
Peergroup
© Newsfile
05.03.2025
HEM
LISTED
TSX
Hemostemix Sells Its 23rd ACP-01 Therapy Convertible Debenture
News Preview
Calgary, Alberta--(Newsfile Corp. - March 5, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely treated 498 patients for various forms of cardiovascular disease, including peripheral arterial disease, chronic limb threatening ischemia, non i...
Themefolio
Profiler
Peergroup
© Newsfile
20.02.2025
HEM
LISTED
TSX
RETRANSMISSION: Hemostemix Licenses CytoImmune's BioReactor Technologies
News Preview
Calgary, Alberta--(Newsfile Corp. - February 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that secures its leadership position in the global stem cell market. By securing an arm's length perpetual, royalty-free global license to CytoImmune's Bior...
Themefolio
Profiler
Peergroup
© Newsfile
19.02.2025
HEM
LISTED
TSX
Hemostemix Licenses CytoImmune's BioReactor Technologies
News Preview
Calgary, Alberta--(Newsfile Corp. - February 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that secures its leadership position in the global stem cell market. By securing an arm's length perpetual, royalty-free global license to CytoImmune's Bior...
Themefolio
Profiler
Peergroup
© Newsfile
14.02.2025
HEM
LISTED
TSX
Hemostemix Provides Corporate Update
News Preview
Calgary, Alberta--(Newsfile Corp. - February 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that, at the request of the Canadian Investment Regulatory Organization ("CIRO"), it is issuing this news release to clarify and provide additional information regarding its previous announcement...
Themefolio
Profiler
Peergroup
© Newsfile
11.02.2025
HEM
LISTED
TSX
Hemostemix PR Inc. Congratulates Luis Munoz Marin International Airport on Achieving CEIV Pharma Certification
News Preview
San Juan, Puerto Rico--(Newsfile Corp. - February 11, 2025) - Hemostemix PR Inc. proudly congratulates Luis Muñoz Marín International Airport (SJU) on achieving the prestigious CEIV Pharma Certification from the International Air Transport Association (IATA). This milestone reinforces Puerto Rico's status as a global leader in the logisti...
Themefolio
Profiler
Peergroup
© Newsfile
10.02.2025
HEM
LISTED
TSX
Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors
News Preview
Calgary, Alberta--(Newsfile Corp. - February 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is excited to announce that it has engaged ProConsul Capital Ltd. ("ProConsul"), to provide investment marketing consulting services (the "Services") commencing February 6th, 2025. In consideration for the...
Themefolio
Profiler
Peergroup
© Newsfile
04.02.2025
HEM
LISTED
TSX
CytoImmune Subscribes for 1,634,466 Hemostemix Common Shares
News Preview
Calgary, Alberta--(Newsfile Corp. - February 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce that CytoImmune is subscribing USD $336,500 to a non-brokered private placement of Common Shares at today's closing price of $0.295 ($336,500 / $0.69789 = $482,167.68) (1,634,466 Comm...
Themefolio
Profiler
Peergroup
© Newsfile
03.02.2025
HEM
LISTED
TSX
Hemostemix Expands to the Dominican Republic
News Preview
Calgary, Alberta--(Newsfile Corp. - February 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its continued expansion, as the Company brings its revolutionary ACP-01 therapy back to the Dominican Republic. Hemostemix has posted an update on Social Media, sharing an inside look at...
Themefolio
Profiler
Peergroup
© Newsfile
29.01.2025
HEM
LISTED
TSX
Hemostemix Announces First Sales Orders for ACP-01
News Preview
Calgary, Alberta--(Newsfile Corp. - January 29, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its sales of ACP-01 Treatments are gaining traction, following its social media campaign and presentations in Puerto Rico. "Advanced sales of ACP-01 enables the purchaser/pat...
Themefolio
Profiler
Peergroup
© Newsfile
27.01.2025
HEM
LISTED
TSX
Hemostemix Up-lists to TradeGateExchange in Germany
News Preview
Calgary, Alberta--(Newsfile Corp. - January 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its shares commenced trading on the TradeGateExchange.De under symbol 2VF0 today, January 27, 2025."Listing on the TradeGateExchange.De enables Hemostemix to investors in t...
Themefolio
Profiler
Peergroup
© Newsfile
23.01.2025
HEM
LISTED
TSX
Hemostemix Up-Lists to OTCQB While it Presents its Global Scale-Up Strategy at Two Investor Conferences in Puerto Rico
News Preview
Calgary, Alberta--(Newsfile Corp. - January 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its shares will commence trading on the OTCQB under symbol HMTXF today, January 23, 2025, while the Company presents "Welcome to Your Fountain of Youth!" at the Sequire Inve...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
